(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Janux Therapeutics's earnings in 2025 is -$77,742,000.On average, 19 Wall Street analysts forecast JANX's earnings for 2025 to be -$138,079,311, with the lowest JANX earnings forecast at -$184,993,376, and the highest JANX earnings forecast at -$122,403,812. On average, 18 Wall Street analysts forecast JANX's earnings for 2026 to be -$182,661,875, with the lowest JANX earnings forecast at -$318,954,096, and the highest JANX earnings forecast at -$116,190,421.
In 2027, JANX is forecast to generate -$225,841,987 in earnings, with the lowest earnings forecast at -$360,708,087 and the highest earnings forecast at -$170,868,266.